Songjiang Ma - Jan 2, 2025 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Role
President, Director
Signature
/s/ Songjiang Ma
Stock symbol
GYRE
Transactions as of
Jan 2, 2025
Transactions value $
-$47,543
Form type
4
Date filed
1/6/2025, 04:01 PM
Previous filing
Jan 2, 2025
Next filing
Jan 8, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GYRE Common Stock Sale -$24.8K -2K -0.07% $12.40 2.92M Jan 2, 2025 By Spouse F1, F2
transaction GYRE Common Stock Sale -$12.9K -1.17K -0.04% $11.03 2.92M Jan 3, 2025 By Spouse F1, F3
transaction GYRE Common Stock Sale -$9.87K -833 -0.03% $11.85 2.92M Jan 3, 2024 By Spouse F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
F2 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.99 to $12.80. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.73 to $11.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.73 to $12.27. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.